Caplin Point Expands US Portfolio With Four ANDAs And Fresh FDA Nod

Key Developments  
- Caplin Point Laboratories has purchased four approved ANDAs, enhancing its presence in the US generics market  
- The acquired products are expected to be commercialized over the next 12–18 months, subject to regulatory and market conditions  
- Caplin Steriles, the company’s injectable-focused subsidiary, secured final approval from the USFDA for Nicardipine Hydrochloride Injection  
- Nicardipine is used for short-term treatment of hypertension and is a generic equivalent of Cardene, originally marketed by Chiesi USA  
- The approval reinforces Caplin Steriles’ growing injectable portfolio, which now includes 31 approved ANDAs and 20 more under review  
- These developments align with Caplin Point’s strategic focus on expanding its footprint in regulated markets, particularly the US and Latin America  

Sources: Caplin Point Laboratories official press release , MoneyWorks4Me , JM Financial Services